MX2009005461A - N-oxidos de analogos de 4,5-epoxi-morfinano. - Google Patents

N-oxidos de analogos de 4,5-epoxi-morfinano.

Info

Publication number
MX2009005461A
MX2009005461A MX2009005461A MX2009005461A MX2009005461A MX 2009005461 A MX2009005461 A MX 2009005461A MX 2009005461 A MX2009005461 A MX 2009005461A MX 2009005461 A MX2009005461 A MX 2009005461A MX 2009005461 A MX2009005461 A MX 2009005461A
Authority
MX
Mexico
Prior art keywords
oxides
epoxy
morphinanium analogs
morphinanium
analogs
Prior art date
Application number
MX2009005461A
Other languages
English (en)
Inventor
Amy Qi Han
Julio Perez
Yakov Rotshteyn
Govindaraj Kumaran
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of MX2009005461A publication Critical patent/MX2009005461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen los N-óxidos novedosos de los análogos de 4,5-epoxi-morfinano. También se describen composiciones farmacéuticas que contienen los N-óxido de los análogos de 4,5-epoxi-morfinano y método para sus usos farmacéuticos. Los compuestos descritos son útiles, inter alia, como moduladores de receptores de opioide.
MX2009005461A 2006-11-22 2007-11-21 N-oxidos de analogos de 4,5-epoxi-morfinano. MX2009005461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86710406P 2006-11-22 2006-11-22
PCT/US2007/085428 WO2008070462A2 (en) 2006-11-22 2007-11-21 N-oxides of 4,5-epoxy-morphinanium analogs

Publications (1)

Publication Number Publication Date
MX2009005461A true MX2009005461A (es) 2009-08-28

Family

ID=39492974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005461A MX2009005461A (es) 2006-11-22 2007-11-21 N-oxidos de analogos de 4,5-epoxi-morfinano.

Country Status (9)

Country Link
US (1) US20080234306A1 (es)
EP (1) EP2099456A2 (es)
JP (1) JP2010510326A (es)
CN (1) CN101678016A (es)
AU (1) AU2007329590A1 (es)
BR (1) BRPI0719327A2 (es)
CA (1) CA2670342A1 (es)
MX (1) MX2009005461A (es)
WO (1) WO2008070462A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200815451A (en) 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
WO2009155259A1 (en) * 2008-06-17 2009-12-23 Mallinckrodt Inc. Processes for the preparation of 6- beta-hydroxy morphinan compounds
CN101607963B (zh) * 2008-06-20 2013-04-03 重庆医药工业研究院有限责任公司 吗啡喃衍生物及其制备方法
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN102325776A (zh) * 2009-02-23 2012-01-18 马林克罗特公司 (+)-吗啡喃*季盐及其制备方法
US8563724B2 (en) * 2009-02-23 2013-10-22 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CN102325777B (zh) * 2009-02-23 2015-08-12 马林克罗特公司 (+)-吗啡喃*n-氧化物及其制备方法
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CA2782529C (en) 2009-12-04 2015-05-26 Alkermes, Inc. Morphinan derivatives for the treatment of drug overdose
EP2995614B8 (en) 2010-06-11 2018-03-28 Rhodes Technologies Inc. Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
AU2011276978B2 (en) * 2010-07-08 2015-01-29 Alkermes Pharma Ireland Limited Process for the synthesis of substituted morphinans
EP2603511B1 (en) * 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
EP3446565B1 (en) 2010-08-23 2023-11-01 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
EP3042908A1 (en) * 2011-05-02 2016-07-13 Brock University Intermediates in the preparation of morphine analogs
JP2014526467A (ja) 2011-09-08 2014-10-06 マリンクロッド エルエルシー 中間体の単離なしでのアルカロイドの調製
ES2692885T3 (es) 2011-10-03 2018-12-05 Johnson Matthey Plc Proceso para preparar buprenorfina
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
MX2014009353A (es) * 2012-02-03 2015-11-06 Univ Brock Procedimiento para la preparacion de analogos de morfina mediante la reaccion de reactivos organometalicos con una oxazolidina derivada a partir de morfinanos.
US9315514B2 (en) * 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
JP6100917B2 (ja) 2012-12-14 2017-03-22 パーデュー、ファーマ、リミテッド、パートナーシップ ピリドンモルフィナン類似体およびオピオイド受容体に対する生物活性
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
ES2621305T3 (es) 2012-12-14 2017-07-03 Purdue Pharma Lp Morfinanos espirocíclicos y su uso
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
EP2941430B1 (en) * 2012-12-28 2017-04-26 Purdue Pharma LP 7,8-cyclicmorphinan analogs
ES2653265T3 (es) 2012-12-28 2018-02-06 Purdue Pharma Lp Morfinanos sustituidos y el uso de éstos
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
ES2784690T3 (es) 2013-12-05 2020-09-29 Univ Bath Nuevos compuestos opioides y sus usos
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
CN105985348B (zh) * 2015-02-12 2019-02-01 正大天晴药业集团股份有限公司 一种溴甲基纳曲酮的制备方法
CN106554357B (zh) * 2015-09-25 2018-09-11 宜昌人福药业有限责任公司 吗啡衍生物晶型i及其制备方法和用途
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
CN111606816A (zh) * 2017-05-22 2020-09-01 扬子江药业集团有限公司 一种地佐辛晶型及其制备方法
CA3106995A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2022212868A1 (en) * 2021-04-01 2022-10-06 University Of Cincinnati Long lasting opioid reversal using hydrogen peroxide-induced release in blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990617A (en) * 1985-12-02 1991-02-05 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
US6825205B2 (en) * 2002-09-25 2004-11-30 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof

Also Published As

Publication number Publication date
EP2099456A2 (en) 2009-09-16
CA2670342A1 (en) 2008-06-12
BRPI0719327A2 (pt) 2014-02-04
WO2008070462A3 (en) 2008-10-16
CN101678016A (zh) 2010-03-24
JP2010510326A (ja) 2010-04-02
AU2007329590A1 (en) 2008-06-12
US20080234306A1 (en) 2008-09-25
WO2008070462A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
HK1120442A1 (en) Novel opioid antagonists
WO2006034039A3 (en) Substituted morphinans and methods of their use
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
HK1112238A1 (en) Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
MY153915A (en) Organic compounds
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
TW200612892A (en) Novel compounds
WO2009132313A3 (en) Morphinan derivatives of organic and inorganic acids
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
TW200738659A (en) Novel compounds
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
JO2578B1 (en) Compounds Theophene benzimidazole
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
DE602004024213D1 (en) Aminopropanolderivate
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
SG158091A1 (en) Imidazoazepinone compounds
GEP20084492B (en) New 4-benzylidene-piperidin derivatives
UA97965C2 (ru) Замещенные пиразолы, содержащая их композиция, способ их получения и применения